

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Commercial immunoglobulin products now contain neutralising antibodies against SARS-CoV-2 spike antibody which are detectable in patient serum

Vinit Upasani¹, Mary O’Sullivan², Fernando Moreira², Sarita Workman², Andrew Symes², Siobhan O Burns^{1,2}, Susan Tadros², Laura McCoy¹, David M Lowe^{1,2}

1. Institute of Immunity and Transplantation, University College London, London, UK.
2. Department of Clinical Immunology, Royal Free London NHS Foundation Trust, London, UK

Correspondence: Dr David M Lowe
Institute of Immunity and Transplantation
University College London
Pears Building
Rowland Hill Street
NW3 2PP
London, UK

d.lowe@ucl.ac.uk

Key words: SARS-CoV-2; spike antibody; IVIG; neutralisation; immunodeficiency

Running title: SARS-CoV-2 spike antibodies in IVIG

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Abstract: Antibody-deficient patients respond poorly to COVID-19 vaccination and are at risk of severe or prolonged infection. Prophylaxis with anti-SARS-CoV-2 monoclonal antibodies has been considered. We here demonstrate that many immunoglobulin preparations now contain neutralising anti-SARS-CoV-2 antibodies which are transmitted to patients in good concentrations, albeit with significant differences between products.

Text:

1 Primary and secondary antibody deficiencies are characterised by impaired ability to mount a
2 functional humoral immune response (1). Patients with these conditions have either significantly
3 decreased or no antibody responses after most infections or vaccinations compared to healthy
4 individuals (1), including to SARS-CoV-2 (2,3). These patients rely on long-term infusions with
5 commercial intravenous immunoglobulin (IVIG) products, which is collectively referred to as
6 Immunoglobulin Replacement Therapy (IRT), for protection against infectious diseases. The
7 IVIG products used for IRT are derived from the plasma of thousands of pre-screened healthy
8 donors containing natural antibodies against various antigens.

9 Since the beginning of the SARS-CoV-2 pandemic, individuals with antibody deficiencies have
10 been at considerable risk from the infection and have shown increased hospitalisation rates and
11 mortality (2,4). They are also at risk of prolonged and relapsing COVID-19 disease (3). In the
12 absence of a robust humoral vaccination response, attention has been given recently to other
13 potential prophylactic strategies such as long-acting monoclonal antibodies against the spike (S)
14 protein of SARS-CoV-2 (5). We hypothesised that, given the ubiquity of vaccination and/or
15 natural infection even by 2021, immunoglobulin preparations prepared from plasma of healthy
16 donors may now contain levels of antibody that confer some protection, reducing the imperative
17 for other prophylaxis. Therefore, in this study, we evaluated the antibody response against
18 SARS-CoV-2 in a cohort of patients before and after undergoing infusion with commercial IVIG
19 products. Furthermore, in these paired samples and the products themselves, we estimated the
20 neutralising antibody titres against SARS-CoV-2 wildtype virus and Omicron variant using an *in*
21 *vitro* luminescence-based neutralisation assay.

22 We recruited 35 individuals with immunodeficiencies on IRT and 7 healthy controls. All donors
23 provided written informed consent under protocols approved by a UK National Health Service
24 (NHS) research ethics committee (Hampstead Research Ethics Committee, Refs 04/Q0501/119
25 and 08/H0720/46). Blood sampling was performed from the patients in the clinic before and
26 immediately after an IVIG infusion was completed. The patient demographic data are
27 summarised in Supplementary Table 1. The most common diagnoses were common variable
28 immunodeficiency (CVID) and secondary hypogammaglobulinemia. All patients had been on
29 regular IVIG for at least 6 months and IgG trough levels were generally >7 g/L. Patients at our
30 centre receive a range of immunoglobulin products with random selection, unless there are
31 specific contraindications or adverse reactions. All patients had received at least 2 vaccinations
32 against SARS-CoV-2. 20 patients reported a prior history of COVID-19 (two patients reported 2

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

33 infections) with around half of episodes treated and others usually resolving spontaneously. Of
34 note, one patient had received sotrovimab treatment within the previous 2 weeks.

35 First, we determined the titres of antibodies directed against SARS-CoV-2 spike protein using a
36 commercial immunoassay (Elecsys® Anti-SARS-CoV-2 S, Roche). Samples with titres >2500
37 U/mL were diluted 10-fold and repeated, resulting in a maximum titre of 25,000 U/mL. Most
38 patients showed a significant increase in anti-S antibody titres post-infusion with
39 immunoglobulin products (Figure 1A) ($p < 0.01$) with the median titre increasing from 2123
40 U/mL pre-infusion to 10600 U/mL post-infusion. Upon classification based on IVIG product
41 administered, this increase in anti-S antibody titres was observable in most patients receiving
42 Privigen or Octagam. Responses in patients receiving Intratect were variable, perhaps indicating
43 batch to batch variation. Post-infusion titres in patients who received Flebogamma were
44 relatively modest while for Iqymune, S antibody titres remained unchanged or decreased slightly
45 and some were very low (<100 U/mL). The patient who had received sotrovimab recently had a
46 titre of >25,000 U/mL even pre-infusion (receiving Privigen). Three patients receiving Intratect
47 had similarly high titres pre-infusion even in the absence of recent treatment.

48 Next, neutralising antibody titres against wild-type SARS-CoV-2 and Omicron were determined
49 using a luminescence-based neutralisation assay as described previously (6). Briefly, serially
50 diluted serum samples or neat immunoglobulin products were incubated in a 96-well plate with a
51 HIV-based pseudovirus expressing S protein of wild-type SARS-CoV-2 virus or the omicron
52 variant on its surface. HeLa cells engineered to express ACE2, a surface attachment factor for
53 SARS-CoV-2 (7), were added to the respective wells. After 3 days of incubation, cells were
54 lysed, and plates were read upon addition of a luminescent substrate. Neutralisation capacity of
55 the serum sample is expressed in terms of inhibitory dilution 50 (ID_{50}), i.e., the serum dilution at
56 which 50% of infection is inhibited compared to the virus alone. Neutralisation titres against
57 both wild-type and Omicron variants significantly increased post-infusion with IVIG products
58 (Figure 1B). However, baseline neutralisation titres against wild-type virus were higher than
59 Omicron prior to infusion with IVIG products (median ID_{50} : 1437 vs 925).

60 We also compared the SARS-CoV-2 neutralisation titres of patients with immunodeficiencies
61 undergoing IVIG infusions to healthy individuals. Neutralising antibody titres against both wild-
62 type and Omicron viruses were significantly lower in patients prior to infusion with IVIG
63 products compared to healthy donors (median ID_{50} : Wild-type 1437 vs 27574; Omicron 925 vs
64 7563, $p < 0.0001$ and $p < 0.001$ respectively) but were restored to levels comparable to those
65 observed in healthy donors after infusion, albeit with considerable heterogeneity (median ID_{50} :
66 Wild-type 4985 vs 27574; Omicron 4932 vs 7563, no statistically significant differences) (Figure

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

67 1C). There were no statistical differences between S Ab concentrations or neutralisation titres
68 (pre- or post-infusion) between patients with a history of COVID-19 in the last 6 months versus
69 those who had COVID-19 more than 6 months previously.

70 To confirm that neutralisation was derived from the immunoglobulin products, we tested some
71 of the corresponding batches of IVIG products (except Gammalex) used on those days in the
72 clinic at neat concentration followed by 5-fold serial dilutions in the SARS-CoV-2 neutralisation
73 assay. All products demonstrated detectable neutralisation varying between ID50 of 1:25000 and
74 1:2x10⁷, higher titres overall than observed in patient serum. However, in general products
75 showed lower neutralisation activity against Omicron compared to the wild-type virus
76 (Supplementary Figure 1A) in line with observations in convalescent and vaccinated
77 populations. Batches of Intratect and Privigen showed significantly higher neutralisation activity
78 against wild-type virus compared to other products, especially Flebogamma and Iqymune, which
79 is in line with S Ab results observed previously. Octagam neutralised the Omicron variant poorly
80 compared to wild-type virus, while Iqymune neutralised Omicron somewhat better than wild-
81 type virus despite patients on Iqymune generally having lower anti-S and neutralising antibody
82 titres (Supplementary Figure 1A). However, maximum titre against either virus with this product
83 was below 1:10⁵.

84 To ascertain whether these differences between IVIG products are reflected in the neutralising
85 antibody titres of patient serum, post-infusion neutralisation titres were compared based on the
86 IVIG product received. Lower neutralisation against wild-type virus was seen in serum from
87 patients who received Iqymune, consistent with other results, but there were no clear differences
88 between products for Omicron. However, a high degree of patient-dependent variability in
89 neutralisation titres was observed in our cohort (Supplementary Figure 1B). This is likely to
90 reflect varying immunological outcomes from prior vaccination or infection with some patients
91 able to generate an antibody response and others not. However, the overall improvement in
92 neutralisation across the cohort from pre- to post-infusion (Figure 1) suggests that most IVIG
93 products are conferring additional benefit, even against omicron variants. We have not here
94 investigated subcutaneous immunoglobulin products although we anticipate that findings would
95 be similar.

96 In summary, we have demonstrated that, in mid-2022, most commercial IVIG preparations now
97 contain neutralising anti-SARS-CoV-2 spike antibodies and that these are detectable in patient
98 serum after infusion. The majority of people have good levels of S antibody, at levels that would
99 render them ineligible for current prophylaxis studies (eg
100 <https://clinicaltrials.gov/ct2/show/NCT04870333>). Although antibody-deficient patients have

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

101 lower neutralisation capacity than healthy controls immediately pre-infusion (at IgG trough), this
102 is largely restored by infusion. However, there is considerable variability between products and
103 potentially between batches: this presumably relates to the timing of plasma harvest and is likely
104 to improve over time. The impact of this heterogeneity on neutralisation of omicron variants is
105 less clear and we note that many of our patients had previously had COVID-19, albeit with full
106 clinical recovery. However, this finding should reassure patients and clinicians that they are
107 likely to have at least relative protection against COVID-19.

108

109

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

110 **Funding:** Nil

111 **Potential conflicts of interest:** S.W. has received personal fees from UCB and LFB
112 Biopharmaceuticals and sponsorship to attend meetings from Biotest, CSL Behring and
113 Octapharma. A.S. has received personal fees for a webinar from CSL Behring. S.O.B. has
114 received grant support from CSL Behring, personal fees or travel expenses from
115 Immunodeficiency Canada/IAACI, CSL Behring, Baxalta US Inc and Biotest and fees as an
116 external expert for GSK. D.M.L has received personal fees from Gilead for an educational video
117 on COVID-19 in immunodeficiency, from Merck for a roundtable discussion on risk of COVID-
118 19 in immunosuppressed patients and speaker fees from Biotest. D.M.L. also holds research
119 grants from GSK and Bristol Myers Squibb, outside the current work. All other authors declare
120 no conflicts of interest.

121 **Acknowledgements:** The authors would like to thank Rosemarie Ford and Dylan Jankovic of
122 Institute of Immunity and Transplantation, UCL for their technical input with the neutralisation
123 assay.


124

125 **References**

- 126 1. McCusker, C., Upton, J., & Warrington, R. (2018). Primary immunodeficiency.
127 *Allergy, Asthma & Clinical Immunology*, 14(S2), 61. [https://doi.org/10.1186/s13223-018-](https://doi.org/10.1186/s13223-018-0290-5)
128 0290-5
- 129 2. Shields, A. M., Faustini, S. E., Hill, H. J., Al-Taei, S., Tanner, C., Ashford, F. (2022).
130 SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from
131 the COV-AD Study. *Journal of Clinical Immunology*. [https://doi.org/10.1007/s10875-022-](https://doi.org/10.1007/s10875-022-01231-7)
132 01231-7
- 133 3. Brown, L.-A. K., Moran, E., Goodman, A., Baxendale, H., Bermingham, W.,
134 Buckland, M. (2022). Treatment of chronic or relapsing COVID-19 in immunodeficiency.
135 *Journal of Allergy and Clinical Immunology*, 149(2), 557-561.e1.
136 <https://doi.org/10.1016/j.jaci.2021.10.031>
- 137 4. Shields, A. M., Anantharachagan, A., Arumugakani, G., Baker, K., Bahal, S.,
138 Baxendale, H. (2022). Outcomes following SARS-CoV-2 infection in patients with primary
139 and secondary immunodeficiency in the UK. *Clinical and Experimental Immunology*.
140 <https://doi.org/10.1093/cei/uxac008>
- 141 5. Nguyen, Y., Flahault, A., Chavarot, N., Melenotte, C., Cheminant, M., Deschamps, P.
142 (2022). Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-
143 19 among 1112 severely immunocompromised patients. *Clinical Microbiology and Infection*.
144 <https://doi.org/10.1016/j.cmi.2022.07.015>
- 145 6. Rees-Spear, C., Muir, L., Griffith, S. A., Heaney, J., Aldon, Y., Snitselaar, J. L.,
146 Thomas, P., Graham, C., Seow, J., Lee, N., Rosa, A., Roustan, C., Houlihan, C. F., Sanders,
147 R. W., Gupta, R. K., Cherepanov, P., Stauss, H. J., Nastouli, E., Doores, K. J., ... McCoy, L.
148 E. (2021). The effect of spike mutations on SARS-CoV-2 neutralization. *Cell Reports*,
149 34(12), 108890. <https://doi.org/10.1016/j.celrep.2021.108890>
- 150 7. Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J.,
151 Yang, D., Xu, Y., Cao, Z., & Gao, Z. (2020). Role of angiotensin-converting enzyme 2
152 (ACE2) in COVID-19. *Critical Care*, 24(1), 422. [https://doi.org/10.1186/s13054-020-03120-](https://doi.org/10.1186/s13054-020-03120-0)
153 0
- 154

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

155 **Figure 1: Humoral immune responses in patients with PIDs receiving IVIG products. A.** SARS-
156 CoV-2 S Ab titres in serum samples taken from patients pre- and post-infusion with IVIG products:
157 results are presented from all patients and according to product received. **B.** Comparison of neutralising
158 antibody titres (ID₅₀) against SARS-CoV-2 wild-type and Omicron viruses in serum samples from
159 patients pre- and post-infusion with IVIG products. **C.** Neutralising antibody titres in comparison with
160 healthy donors. *P*-values were calculated using Wilcoxon paired t test for comparing two groups and
161 Kruskal-Wallis test with Dunn's post-hoc test for comparing three groups (***P*<0.01; *** *P*<0.001; ****
162 *P*<0.0001).



163

164

165


Supplementary Material

Age (years)	Median Range	60 20 – 86
Sex	Male Female	12 23
Diagnosis	CVID XLA Other / undefined primary hypogammaglobulinemia Secondary hypogammaglobulinemia	12 2 9 12
Duration on IVIG	6 months – 1 year 1 – 3 years >3 years	1 4 30
Infusion frequency	2-weekly 3-weekly 4-weekly 5-weekly 6-weekly	1 4 18 3 9
Last IgG trough (g/L)	Median Range	9.3 4.1 – 13.7
Received COVID-19 vaccination	No Yes 2 vaccinations 3 vaccinations 4 vaccinations 5 vaccinations	0 35 3 7 19 6
Time since last vaccination (days)	Median Range	124 27 – 410
Known previous COVID-19	No Yes, once Yes, twice	15 18 2
COVID-19 episodes	Untreated Sotrovimab treatment Remdesivir treatment Nirmatrelvir/ritonavir treatment Unknown treatment	10 5 1 1 5
Time since COVID-19 (days)	Median Range	131 9 – 857

Supplementary table 1: Patient demographics and clinical details.

CVID – common variable immunodeficiency; XLA – X-linked agammaglobulinemia; IVIG – intravenous immunoglobulin; g/L – grams per litre

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .



Supplementary figure 1: (A) Product wise comparison of neutralising antibody titres (ID_{50}) against SARS-CoV-2 wild-type and Omicron viruses in neat IVIG products used for infusions in patients. (B) Neutralising antibody titres (ID_{50}) against SARS-CoV-2 wild-type and Omicron viruses in patient serum post-infusion with IVIG products. P -values were calculated using non-parametric Mann-Whitney test (* $P < 0.05$; ** $P < 0.01$).